Related Experiment Video
Updated: Jul 4, 2026
11:01
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
Published on: November 23, 2016
Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future
Muhammad Akram Mohd Noordin1, Ahmed Abdulkareem Najm2,3, Lim Huei Wern1
1Department of Biological Sciences and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, 43600 UKM, Bangi, Selangor, Malaysia.
Current Medicinal Chemistry
|July 3, 2026
Summary
This study assessed the preliminary safety and ADMET properties of AtMP2, a peptide with anticancer potential. AtMP2 showed favorable characteristics, suggesting it
Area of Science:
- Pharmacology and Toxicology
- Peptide Therapeutics
- Cancer Research
Background:
- Breast cancer is a leading cause of cancer mortality worldwide.
- Developing safe and selective anticancer agents is a critical research area.
- AtMP2, a synthetic peptide from climbing perch mucus, shows prior anticancer activity against breast cancer cells.
Purpose of the Study:
- To investigate the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) characteristics of AtMP2.
- To evaluate the preliminary in vivo safety profile of AtMP2.
- To assess AtMP2's potential as a peptide-based therapeutic candidate.
Main Methods:
- In silico ADMET prediction using ADMETlab 2.0.
- In vitro assays for lipophilicity, protein binding, metabolic stability, and cell permeability.
- Cytotoxicity and antibacterial activity assessments.
- Acute and sub-acute toxicity studies in BALB/c mice.
Main Results:
- AtMP2 is hydrophilic with high plasma and microsomal unbound fractions.
- Moderate metabolic stability and intrinsic clearance were observed.
- No cytotoxicity to mammalian cells; retained antibacterial activity.
- No mortality or significant adverse effects in mice at doses up to 15 mg/kg.
Conclusions:
- AtMP2 exhibits promising preliminary ADMET and short-term safety profiles for an early-stage peptide.
- The study supports further investigation of AtMP2 as a potential therapeutic agent.
- Further pharmacokinetic, safety, and efficacy studies are warranted.
